NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,346,757 | -38.6% | 595,938 | -13.1% | 0.01% | -40.0% |
| Q3 2022 | $2,195,000 | -15.8% | 685,938 | 0.0% | 0.02% | -28.6% |
| Q2 2022 | $2,606,000 | -29.5% | 685,938 | 0.0% | 0.02% | -16.0% |
| Q1 2022 | $3,697,000 | -26.0% | 685,938 | +124.1% | 0.02% | -40.5% |
| Q1 2021 | $4,998,000 | -4.0% | 306,085 | 0.0% | 0.04% | +2.4% |
| Q4 2020 | $5,204,000 | -0.7% | 306,085 | -3.1% | 0.04% | -16.3% |
| Q3 2020 | $5,241,000 | -28.4% | 315,929 | 0.0% | 0.05% | -36.4% |
| Q2 2020 | $7,317,000 | -10.2% | 315,929 | -18.2% | 0.08% | -14.4% |
| Q1 2020 | $8,145,000 | -2.2% | 386,000 | 0.0% | 0.09% | +1.1% |
| Q4 2019 | $8,332,000 | +17.3% | 386,000 | -1.0% | 0.09% | -5.3% |
| Q3 2019 | $7,104,000 | -51.0% | 390,000 | -4.7% | 0.09% | -48.1% |
| Q2 2019 | $14,497,000 | +0.6% | 409,247 | -4.6% | 0.18% | -1.6% |
| Q1 2019 | $14,408,000 | -1.8% | 428,791 | -3.9% | 0.18% | -18.2% |
| Q4 2018 | $14,666,000 | -45.2% | 446,206 | +1.7% | 0.22% | -36.8% |
| Q3 2018 | $26,743,000 | +300.4% | 438,702 | +220.7% | 0.36% | +235.8% |
| Q2 2018 | $6,679,000 | -30.5% | 136,781 | -15.0% | 0.11% | -36.1% |
| Q4 2017 | $9,615,000 | +54.1% | 161,000 | -38.1% | 0.17% | +52.3% |
| Q3 2017 | $6,238,000 | +38.1% | 259,900 | +12.5% | 0.11% | +28.2% |
| Q2 2017 | $4,516,000 | +102.5% | 231,000 | +143.2% | 0.08% | +97.7% |
| Q1 2017 | $2,230,000 | +3.9% | 95,000 | -45.7% | 0.04% | -12.2% |
| Q4 2016 | $2,147,000 | -37.5% | 175,000 | -12.5% | 0.05% | -41.0% |
| Q3 2016 | $3,436,000 | -20.3% | 200,000 | -34.0% | 0.08% | -25.9% |
| Q2 2016 | $4,312,000 | -23.1% | 303,000 | -26.1% | 0.11% | -20.0% |
| Q1 2016 | $5,607,000 | -33.5% | 410,000 | -18.0% | 0.14% | -37.8% |
| Q4 2015 | $8,428,000 | +25.4% | 500,200 | -18.4% | 0.22% | +36.4% |
| Q3 2015 | $6,721,000 | +22.1% | 613,200 | +39.4% | 0.16% | +43.5% |
| Q2 2015 | $5,504,000 | +56.3% | 440,000 | +37.5% | 0.12% | +62.0% |
| Q1 2015 | $3,521,000 | -25.5% | 320,000 | +4.9% | 0.07% | -28.3% |
| Q4 2014 | $4,728,000 | – | 305,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |